ADPH receives allotment of antibody therapeutic drug used to treat COVID-19

Local News

BIRMINGHAM, Ala. (WIAT) — The Alabama Department of Public Health says it received an allotment of a newly authorized antibody drug used to treat patients with COVID-19.

ADPH tells CBS 42 that they were given an undisclosed amount of bamlanivimab. The drug had been given an emergency use authorization from the FDA on Monday.

According to the FDA, bamlanivimab has been shown in clinical trials to reduce coronavirus-related hospitalizations. The drug is designed for those who have contracted the virus and are at a higher risk for developing more severe symptoms.

Bamlanivimab has not been authorized by the FDA to be used for patients that have been hospitalized due to COVID-19 or require oxygen therapy due to the virus, ADPH reports.

As of now, ADPH is working on developing a plan to distribute the drug to those who may need it.

Read ADPH’s full statement on the shipment of bamlanivimab below:

“Yesterday evening, the Alabama Department of Public Health received an allotment of the therapeutic drug bamlanivimab for treatment of some patients with COVID-19. This therapeutic is approved for certain patients who have medical criteria that put them at high risk for progressing to severe COVID-19 and/or hospitalization. This group includes persons who are 65 years of age or older, or who have certain chronic medical conditions. Bamlanivimab is an IV drug treatment and certain requirements must be met in order to use this agent. The department is working with providers to develop a strategic plan for distribution and use of bamlanivimab.”

Alabama Department of Public Health

The FDA has more information on bamlanivimab and its emergency use authorization for the drug. You can find out more by clicking here.


Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.